Posters
Choroidal thickness changes in patients with exudative age-related macular degeneration treated with aflibercept in one-year follow-up
Poster Details
First Author: I.Jamiołkowska POLAND
Co Author(s): M. Figurska M. Rękas
Abstract Details
Purpose:
The presentation discusses the choroidal thickness changes in treatment naive patients with exudative age-related macular degeneration treated with aflibercept.
Setting:
Warsaw, Military Institute of Medicine, Department of Ophthalmology.
Methods:
Thirty-six patients (36 eyes) aged 78.3±8.7 years were qualified for a prospective, randomized 12-month study. Aflibercept was administered monthly for 3 months than biomonthly in fixed regimen. Retinal and choroidal thickness was measured manually on optical coherence tomography scans.
Results:
After 12 months of follow-up, patients gained on average 8.5 letters (p<0.001). Central retinal thickness reduced from 337,7±126,5 µm to 272,1±123,1 µm, (p<0,05). Subfoveal choroidal thickness reduced significantly after loading dose of aflibercept from 190,2 ± 97,7 µm to 177,4 ± 90,0 µm, (p<0,05). Subfoveal choroidal thickness reduction was not significant in 12 month observation, (p=0,078). Choroidal thickness reduced significantly nasally from the fovea, (p<0,05). Subfoveal choroidal thickness reduced in the group with visual acuity improvement from 182,8 ± 91,43 µm to 164,0 ± 86,3 µm after 12 months, (p>0,05), but not in groups with visual deterioration and stabilization, (p>0,05).
Conclusions:
Aflibercept treatment in age-related macular degeneration does not influence choroid in one year observation. Subfoveal choroidal thickness is reduced in patients with neovascular age-related macular degeneration treated with aflibercecpt after loading dose. Choroidal thickness reduction was observed nasal from the fovea. Reduction of choroidal thickness was observed in patients with visual acuity improvement, but not in patients with stabilization or deterioration of visual acuity.
Financial Disclosure:
None
